Lymphoma Clinical Trials in San Francisco

Showing 181-183 of 183 trials

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

NCT00057447

Evaluate the safety and efficacy of the dosing schedule of subcutaneous interferon gamma-1b (IFN g-1b) administered 3 times per week with Rituximab for 4 weeks, in patients with progressive or relapsed low-grade Non-Hodgkin's Lymphoma (NHL) International study with sites in the Czech Republic and Poland

Non-Hodgkin's Lymphoma

InterMune24 participantsStarted Mar 2003

Brisbane, California, United States

COMPLETEDPHASE210 miles

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

NCT00090090

To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).

Mantle Cell LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Spectrum Pharmaceuticals, Inc114 participantsStarted Apr 2004

Berkeley, California, United States • Burbank, California, United States • Los Angeles, California, United States +4 more locations

UNKNOWNPHASE2679 miles

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

NCT00039156

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of BAY 59-8862 in treating patients who have refractory non-Hodgkin's lymphoma.

Lymphoma

TheradexStarted Jan 2002

Miami Beach, Florida, United States • Chicago, Illinois, United States • Shreveport, Louisiana, United States +12 more locations

Safety of Interferon Gamma-1b With Rituximab in Non-Hodgkin's Lymphoma Patients

Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma

BAY 59-8862 in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Lymphoma Trials in Other Cities

Other Conditions in San Francisco